Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096964 | 1.00 | USP2 (0.49) | USP2CA12CA1CA2CA9 | |
| SCHEMBL13096962 | 0.86 | NOTUM (0.54) | MAPTHTR1AHTR7ALDH1A1FFAR4 | |
| SCHEMBL3096685 | 0.86 | NOTUM (0.54) | MAPTHTR1AHTR7ALDH1A1FFAR4 | |
| SCHEMBL8124983 | 0.83 | NPSR1 (0.56) | CA12CA1CA2CA9TP53 | |
| SCHEMBL13096952 | 0.83 | HTR1A (0.46) | USP2SMN1; SMN2HTR1AHTR7ALDH1A1 | |
| SCHEMBL3103804 | 0.83 | HTR1A (0.46) | USP2SMN1; SMN2HTR1AHTR7ALDH1A1 | |
| SCHEMBL13096967 | 0.81 | POLB (0.60) | USP2SLC6A9SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL3097846 | 0.81 | POLB (0.60) | USP2SLC6A9SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL3103771 | 0.80 | TP53 (0.61) | CA12CA1CA2CA9TP53 | |
| SCHEMBL3098854 | 0.80 | TP53 (0.61) | CA12CA1CA2CA9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | claimed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | claimed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | claimed |
| US-8604190-B2 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | VDAC1, HVCN1, TRPV1 | USP2 4168/4885CA12 4097/4885CA1 2962/4885 |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | VDAC1, HVCN1, TRPV1 | USP2 4168/4885CA12 4097/4885CA1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.